Fidia Farmaceutici S.P.A. Sustainability Profile
Fidia Farmaceutici S.P.A., a prominent player in the pharmaceutical industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1946, the company has established itself as a leader in the development of innovative treatments, particularly in the fields of orthopaedics, rheumatology, and gynaecology. Fidia is renowned for its unique hyaluronic acid-based products, which are designed to enhance patient care and improve quality of life. With a strong commitment to research and development, the company has achieved significant milestones, including the introduction of groundbreaking therapies that address unmet medical needs. Fidia's dedication to excellence has positioned it as a trusted name in the pharmaceutical sector, recognised for its contributions to healthcare and its ongoing pursuit of innovation.
DitchCarbon Score
How does Fidia Farmaceutici S.P.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fidia Farmaceutici S.P.A.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fidia Farmaceutici S.P.A.'s reported carbon emissions
In 2024, Fidia Farmaceutici S.P.A. reported total carbon emissions of approximately 19,018,000 kg CO2e, with 19,018,000 kg CO2e attributed to Scope 1 emissions. This marks a slight increase from 2023, where total emissions were about 19,596,000 kg CO2e, comprising 18,705,000 kg CO2e from Scope 1 and 2,024,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Fidia Farmaceutici has not set specific reduction targets or initiatives as part of its climate commitments, and there are no reported climate pledges or SBTi targets. The emissions data is cascaded from the parent company, indicating a corporate family relationship, but specific details on the source organization are not provided. Overall, Fidia Farmaceutici's emissions reflect its operational impact, with a focus on direct emissions management, while further commitments to climate action remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 18,705,000 | 00,000,000 |
| Scope 2 | 2,024,000 | - |
| Scope 3 | - | - |
How Carbon Intensive is Fidia Farmaceutici S.P.A.'s Industry?
How Carbon Intensive is Fidia Farmaceutici S.P.A.'s Location?
Fidia Farmaceutici S.P.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fidia Farmaceutici S.P.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
